Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Although the BRAF inhibitors dabrafenib and vemurafenib have both proven successful against BRAF‐mutant melanoma, there seem to be differences in their mechanisms of action. Here, we show that dabrafenib is more effective at inhibiting the growth of NRAS‐mutant and KRAS‐mutant cancer cell lines than...

Full description

Bibliographic Details
Main Authors: Manali Phadke, Lily L. Remsing Rix, Inna Smalley, Annamarie T. Bryant, Yunting Luo, Harshani R. Lawrence, Braydon J. Schaible, Yian A. Chen, Uwe Rix, Keiran S. M. Smalley
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Molecular Oncology
Subjects:
BRAF
CDK16
chemical proteomics
dabrafenib
melanoma
NEK9
Online Access:https://doi.org/10.1002/1878-0261.12152

Internet

https://doi.org/10.1002/1878-0261.12152

Similar Items